Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
Study sponsor: Revolution Medicines, Inc. · RVMD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-10Estimated
Enrollment · participants430Estimated
Source updated2026-11-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.